Author

Sara E. Prischak

Observed name: Sara Prischak

Institutions: Abramson Cancer Center, Drexel University, University of Pennsylvania

Observed institutions: Abramson Cancer Center, Drexel University, University of Pennsylvania

ORCID: 0009-0009-3097-7721

Observed ORCID: 0009-0009-3097-7721

OpenAlex ID: A5057150688

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

2024 · Grace T. Baek, Gaurav Varma, et al. · Blood · 3

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors

2021 · Jakub Svoboda, Hatcher J Ballard, et al. · Blood · 1

Incidence and Prevalence of Lens Subluxation or Dislocation Following Cataract Surgery in Patients with Uveitis

2026 · Sara E. Prischak, Kayla M. Valenti, et al. · Ocular Immunology and Inflammation

Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma

2026 · Grace Baek, Gaurav Varma, et al. · Blood Advances

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

2024 · Gaurav Varma, Maya C. Rosenberg, et al. · Blood

COVID-19 pandemic experience in patients with Hodgkin lymphoma.

2022 · Sara E. Prischak, Hatcher J. Ballard, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 4

H-index: 1

I10-index: